Pulmonary tuberculosis (TB) and type 2 diabetes mellitus (T2DM) are significant global health burdens that independently impair immune function.When present concurrently, they exacerbate disease severity, reduce treatment effectiveness, and increase mortality.Recent literature suggests a growing bidirectional relationship between these conditions.The purpose of this investigation is to evaluate how T2DM-induced immune dysregulation increases susceptibility to TB and worsens clinical outcomes.A literature review was conducted using PubMed, focusing on articles related to cytokine signaling, immune modulation, T2DM, and tuberculosis.T2DM contributes to impaired immunity primarily through hyperglycemia-induced suppression of cytokines, such as tumor necrosis factor-alpha (TNF-α) and various interleukins (IL-1β, IL-6, and IL-12).This dysregulation compromises macrophage and T-cell responses, increasing the risk of TB activation and reducing treatment efficacy.The rising incidence of both diseases in the United States highlights the urgent need to understand this mechanistic overlap to improve therapeutic strategies.T2DM serves as an independent risk factor for TB due to its immunosuppressive metabolic environment.Recognizing these mechanisms can inform clinical decisions and improve the management of co-affected patients.
No takes yet. Share an insight, caveat, or question.
Banda et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: